Nautilus Biotechnology (NAUT) Net Income towards Common Stockholders (2020 - 2021)
Nautilus Biotechnology's (NAUT) quarterly Net Income towards Common Stockholders came in at -$1.8 million in Q1 2021, down 209.01% quarter-over-quarter from -$576035.0 in Q4 2020.
Nautilus Biotechnology (NAUT) Net Income towards Common Stockholders (2020 - 2021) Analysis & Trends
Nautilus Biotechnology has disclosed Net Income towards Common Stockholders across 2 years of filings, most recently posting -$1.8 million for Q1 2021.
- Net Income towards Common Stockholders for Q1 2021 came in at -$1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was -$1.8 million (changed N/A YoY), and the FY2020 annual result was -$576035.0, changed N/A from the prior year.
- Net Income towards Common Stockholders came in at -$1.8 million for Q1 2021 at Nautilus Biotechnology, down from -$576035.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$174671.0 in Q3 2020 to a low of -$1.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -1.78 Mn |
| Dec 31, 2020 | -576,035.00 |
| Sep 30, 2020 | -174,671.00 |